Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gail Sonenshein
Adecto Pharmaceuticals, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Consortia Therapeutics Inc. and Exarca Pharmaceuticals llc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
These companies are working on controlling bacterial infections and food allergies which are unrelated to Adecto's research.
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
We have identified a protein called ADAM8 on the surface of Triple-Negative Breast Cancer (TNBC) tumors, which lack targeted therapies and account for more than 25% of the 500,000 breast cancer deaths yearly worldwide, and validated it as a target for treatment. As proposed in our Phase I STTR grant, we successfully isolated and characterized highly specific inhibitory mouse monoclonal anti-ADAM8 antibodies (termed ADPs) and identified the top two inhibitors which reduced TNBC tumor growth and spread in mice and improved overall survival. In this Phase II SBIR grant, aims are proposed to identify a first-line chemotherapy that works more effectively in combination with an ADP, humanize our top two antibodies, and perform early safety studies to allow us to select a lead for further development and entry into the clinic, which could revolutionize treatment of TNBC by providing a more effective intervention that improves survival of patients with these very aggressive tumors.
Filed on September 17, 2018.
Tell us what you know about Gail Sonenshein's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.